Roche has provided an updateto the community announcing that they have restarted recruitment of RG6206, an investigational anti-myostatin adnectin, in ambulatory boys with Duchenne. PPMD will be hosting a webinar with Roche in the coming weeks and we look forward to learning more.
Read the update from Roche:
11 April 2018
Dear Duchenne community members,
We are happy to let you know that recruitment of participants into our Phase 2/3 clinical study (study WN40227) with the investigational molecule, RG6206, has now restarted.
RG6206 is an anti-myostatin adnectin which blocks the activity of myostatin and is given by subcutaneous injection (injection under the skin). Clinical study WN40227 is assessing the safety and efficacy of RG6206 in ambulatory boys aged 6-11 years with Duchenne (www.clinicaltrials.gov reference NCT030393686).
Study WN40227 is open to new participants in the US and additional study sites in Europe, Australia, Argentina, Japan, the US, and Canada will be opened in the upcoming months.
Staff
Roche Restarts RG62026 Phase 2/3 Study
by PPMD
Apr 11, 2018
Roche has provided an update to the community announcing that they have restarted recruitment of RG6206, an investigational anti-myostatin adnectin, in ambulatory boys with Duchenne. PPMD will be hosting a webinar with Roche in the coming weeks and we look forward to learning more.
Read the update from Roche: